|
09 Oct 2013 |
The Medicines Company and Alnylam Advance Development Candidate for ALN-PCSsc, a Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 Under Investigation for the Treatment of Hypercholesterolemia
|
|
08 Oct 2013 |
Alnylam Advances Development Candidate for ALN-AS1, a Subcutaneously Administered RNAi Therapeutic Targeting Aminolevulinate Synthase 1 (ALAS-1) for the Treatment of Hepatic Porphyrias
|
|
08 Oct 2013 |
Arrowhead Completes Enrollment in Phase 1 Study of ARC-520 for the Treatment of Chronic Hepatitis B
|
|
08 Oct 2013 |
Isis Earns $7 Million in Milestone Payments from GSK for Advancement of ISIS-GSK3 Rx to Treat Viral Infection
|
|
04 Oct 2013 |
Tekmira Presents TKM-PLK1 Data at 6th Annual North American Neuroendocrine Tumor Society (NA-NETS) Conference
|
|
04 Oct 2013 |
Isis Pharmaceuticals Advances Phase 2 Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
|
|
03 Oct 2013 |
Alnylam and Collaborators Publish Clinical Trial Results with ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia, in The Lancet
|
|
02 Oct 2013 |
StemCells, Inc. Receives FDA Authorization of IND for Spinal Cord Injury
|
|
01 Oct 2013 |
Pluristem's PLX Cells Demonstrate Efficacy in Preclinical Study for Graft versus Host Disease
|
